K. Nakatsuka

发表

Lead‐in treatment with interferon‐β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha‐2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype

A. Tsubota, K. Iwakiri, C. Sakamoto, 2013, Journal of gastroenterology and hepatology.

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b

A. Tsubota, C. Sakamoto, Tamaki Kobayashi, 2013, Journal of gastroenterology and hepatology.

An open‐label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin

A. Tsubota, C. Sakamoto, M. Atsukawa, 2012, Journal of viral hepatitis.

Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.

A. Tsubota, K. Iwakiri, T. Hatori, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients

A. Tsubota, Y. Matsuzaki, K. Iwakiri, 2015, BMC Infectious Diseases.

Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T-lymphocytes induced with B7-1-gene-transfected hepatoma cells.

Y. Nakagawa, H. Takahashi, K. Nakatsuka, 1999, Journal of hepatology.

Serum 25‐hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load

A. Tsubota, K. Iwakiri, C. Sakamoto, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin‐10 secretion to assist in hepatitis C virus clearance

C. Sakamoto, H. Tamura, M. Shimizu, 2012, Journal of gastroenterology and hepatology.

Wedged Hepatic Venous Pressure Does Not Reflect Portal Pressure in Patients with Cirrhosis and Hepatic Veno–Venous Communications

C. Sakamoto, Y. Narahara, K. Nakatsuka, 2007, Digestive Diseases and Sciences.

Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells

C. Sakamoto, Y. Nakagawa, M. Shimizu, 2013, Immunology and cell biology.

Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin

A. Tsubota, Y. Matsuzaki, K. Iwakiri, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis

C. Sakamoto, M. Atsukawa, T. Fukuda, 2009, Journal of gastroenterology and hepatology.

Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

C. Sakamoto, Y. Narahara, K. Nakatsuka, 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study

A. Tsubota, K. Iwakiri, C. Sakamoto, 2013, Hepatitis monthly.

Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites

C. Sakamoto, M. Atsukawa, N. Itokawa, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Two cases of alcoholic liver cirrhosis with diffuse intrahepatic arterio-portal shunt treated by transjugular intrahepatic portosystemic shunt

C. Sakamoto, Tamaki Kobayashi, M. Atsukawa, 2011 .

Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance.

Hidemi Takahashi, M. Atsukawa, C. Kawamoto, 2015, World journal of hepatology.

Ribavirin modulates the conversion of human CD4+ CD25− T cell to CD4+ CD25+ FOXP3+ T cell via suppressing interleukin‐10‐producing regulatory T cell

C. Sakamoto, H. Tamura, E. Shinya, 2012, Immunology.

Epigastric pain syndrome accompanying pancreatic enzyme abnormalities was overlapped with early chronic pancreatitis using endosonography

T. Akamizu, K. Iwakiri, S. Futagami, 2017, Journal of clinical biochemistry and nutrition.

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression

K. Iwakiri, S. Futagami, Hidemi Takahashi, 2018, bioRxiv.

Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension

C. Sakamoto, S. Fujimori, M. Atsukawa, 2013, Journal of Gastroenterology.

THE EFFECTS OF PORTAL PRESSURE CHANGE BY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AND SHUNT STENOSIS ON PORTAL HYPERTENSIVE GASTROPATHY

S. Matsuzaka, K. Nakatsuka, H. Kanazawa, 1996 .

Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial

C. Sakamoto, M. Atsukawa, T. Fukuda, 2010, Journal of Gastroenterology.

A CASE OF HEMORRHAGE DUE TO PORTAL HYPERTENSIVE GASTROPATHY SUCCESSFULLY TREATED WITH TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT

S. Matsusaka, Masafumi Kobayashi, K. Nakatsuka, 1994 .

A case of IgG4-related disease with rectal cancer

C. Sakamoto, M. Atsukawa, N. Itokawa, 2011, Clinical journal of gastroenterology.

A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage.

C. Sakamoto, Masafumi Kobayashi, S. Matsuzaka, 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy

A. Tsubota, K. Iwakiri, C. Sakamoto, 2014, European journal of gastroenterology & hepatology.

Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.

A. Tsubota, K. Iwakiri, C. Sakamoto, 2015, Internal medicine.

Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C

A. Tsubota, Hiroki Yamaguchi, K. Iwakiri, 2014, European journal of gastroenterology & hepatology.

For Peer Review Fluvastatin does not exhibit an add -on effect on pegylated - interferon/ribavirin/telaprevir therapy for HCV genotype 1b-infected chronic hepatitis C

A. Tsubota, K. Iwakiri, C. Sakamoto, 2013 .

Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis

C. Sakamoto, M. Atsukawa, N. Itokawa, 2014, Journal of gastroenterology and hepatology.